See the source article by following the link below:
Ceritinib, an ALK inhibitor, outperforms chemotherapy for lung cancer patients who previously failed crizotinib treatment (phase 3 trial)
Ceritinib, an ALK inhibitor, outperforms chemotherapy for lung cancer patients who previously failed crizotinib treatment (phase 3 trial)
No comments:
Post a Comment